SunBio, Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name SunBio, Inc.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 110.2%
- Equity ratio
- 47.6%
- ROE
- 9.7%
- Op. margin
- 36.8%
- Rev. growth
- 57.5%
- Interest coverage
- n/a
Condition flags
- Operating profit for 1 straight year.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | n/a | n/a |
| 2024 | n/a | n/a |
| 2023 | ₩75 | n/a |
No cash dividend in the latest fiscal year, or no value reported.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2022 separate | 79.9% | 55.6% | 3.6% | 2.6% | n/a |
| FY2023 separate | 69.6% | 59.0% | 16.4% | 42.2% | 65.7% |
| FY2024 separate | 125.3% | 44.4% | -0.4% | -6.1% | -29.4% |
| FY2025 separate | 110.2% | 47.6% | 9.7% | 36.8% | 57.5% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | ₩7.4B | ₩12.3B | ₩8.7B | ₩13.7B |
| Operating profit | ₩190.9M | ₩5.2B | -₩533.2M | ₩5.0B |
| Pre-tax income | ₩937.4M | ₩5.5B | -₩227.5M | ₩2.9B |
| Net income | ₩869.3M | ₩4.6B | -₩104.4M | ₩2.8B |
| Total assets | ₩42.9B | ₩47.7B | ₩61.0B | ₩60.7B |
| Total liabilities | ₩19.1B | ₩19.6B | ₩33.9B | ₩31.8B |
| Total equity | ₩23.8B | ₩28.1B | ₩27.1B | ₩28.9B |
| Paid-in capital | ₩6.2B | ₩6.2B | ₩6.2B | ₩6.2B |
| Debt/equity (source value) | 79.9% | 69.6% | 125.3% | 110.2% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1997-06-10
- Listed
- 22/10/05
- Employees
- 29
- Auditor
- 다산회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101111424243
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 선바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.